Wikisage, the free encyclopedia of the second generation, is digital heritage

Bezafibrate

From Wikisage
Revision as of 23:14, 26 February 2019 by Penarc (talk | contribs) (→‎ATC)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and rises HDL-cholesterol[1][2]

[3] [4]

ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).

Links

Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?

ATC

Lipid modifying agents

bezafibrate
[5]

References

References:
  1. ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
  2. ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
  3. ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
  4. ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
  5. ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02

Q577387 at Wikidata  Interwiki via Wikidata

Retrieved from "http://en.wikisage.org/w/index.php?title=Bezafibrate&oldid=7611"